Release Date: February 19, 2025 07:00AM Eastern Standard Time
Light AI Announces Partnership with ELIQUENT Life Sciences to support bringing its cutting-edge AI medical technologies to the U.S. market
Vancouver, B.C. – February 19, 2025 – Light AI Inc. (“Light AI” or
the “Company”) (CBOE CA: ALGO / FSE: 0HC) a global healthcare
technology company focused on developing artificial intelligence
health diagnostic and wellness solutions, today announced its
partnership with ELIQUENT Life Sciences (“ELIQUENT”), a leading regulatory, quality, and safety consulting firm for the life sciences industry. This collaboration aims to help Light AI navigate the complexities of the FDA regulatory pathway and to ensure Light AI’s innovative medical solutions meet all necessary premarket submission requirements.
ELIQUENT will partner with the Company to provide comprehensive support in designing a robust US
Food and Drug Administration (FDA) regulatory strategy, leveraging their deep industry knowledge and extensive experience to facilitate efficient interactions with FDA. This partnership marks a significant milestone in Light AI’s journey to bring cutting-edge medical technologies to the U.S. market.
ELIQUENT Life Sciences delivers integrated solutions that support pharmaceutical, biotechnology, medical device, and combination product companies across the product lifecycle. ELIQUENT’s full-service platform supports innovators across therapeutic modalities, phase-based pathways, and major global markets. The firm’s unprecedented assembly of regulatory leaders, industry experts, and technical specialists collaborate seamlessly to advise clients on the complex process of bringing new therapies to market and manufacturing them to quality standards.
“We are thrilled to partner with ELIQUENT,” says Peter Whitehead, CEO of Light AI. “Their expertise in FDA regulatory strategy is unparalleled, and their support will be invaluable as we develop a clear and effective pathway for our device submissions. This collaboration will help us ensure that our solutions meet the highest standards of safety and efficacy. ELIQUENT‘s proven track record in guiding companies through the regulatory landscape will be instrumental in Light AI’s efforts to achieve timely FDA marketing authorization and ultimately improve patient care through innovative technology.”
“ELIQUENT looks forward to working with the Light AI team as they seek US FDA marketing authorization for their innovative technology,” says Daniel Schultz, Principal of Medical Devices and Combination Products at ELIQUENT.
About Light AI Inc.
(CBOE CA: ALGO / FSE: 0HC)
Light AI Inc. is a healthcare company focused on developing artificial intelligence health diagnostic solutions. Light AI is developing a technology platform which represents the next generation of patient management: it applies AI algorithms to smartphone images—starting with images of Strep A—to identify the disease in seconds. Its patented, app-based solution requires no swabs, lab tests or proprietary hardware of any kind—its hardware platform is the 4.5B smartphones that exist in the world today.
In pre-FDA validation studies, Light AI’s algorithm demonstrated remarkable accuracy in differentiating between viral and bacterial pharyngitis, specifically targeting Group A Streptococcus (GAS). The Company’s algorithm generated pre-Federal Drug Administration (FDA) results were in the range of the “Gold Standard” swab culture currently used for diagnosing GAS achieving a 96.57% accuracy rate that is and a Negative Predictive Value (NPV) of 100%, indicating its high reliability in confirming the absence of Streptococcus A infection. Viral and GAS pharyngitis affects over 600 million people annually worldwide. If left untreated, GAS pharyngitis can lead to serious complications such as Rheumatic Heart Disease (RHD), which imposes a global economic burden exceeding $1 trillion annually. Light AI’s technology offers a significant advancement in the accurate and timely diagnosis of GAS pharyngitis, potentially reducing the incidence of RHD and its associated costs. Light AI’s approach to applying AI to smartphone images can be expanded to other throat conditions, as well as other areas of analysis, such as the human eye and skin. Light AI’s vision is to combine the smartphone with AI in-the-Cloud to create a Digital Clinical Lab that provides quick and accessible diagnosis for countless conditions that today require expensive and time-consuming imaging or lab processes.
Forward-Looking Information:
This news release includes information, statements, beliefs and opinions which are forward-looking, and which reflect current estimates, expectations and projections about future events, including, but not limited to, the contributions to be made by the Company’s partnership with MrBeast, the anticipated inflection of the business, the opportunity related to the commercialization of Light AI’s software and other offerings, and other statements that contain words such as “believe,” “expect,” “project,” “should,” “seek,” “anticipate,” “will,” “intend,” “positioned,” “risk,” “plan,” “may,” “estimate” or, in each case, their negative and words of similar meaning. By its nature, forward-looking information involves a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking information. These risks, uncertainties and assumptions could adversely affect the outcome of the plans and events described herein. Readers should not place undue reliance on forward-looking information, which is based on the information available as of the date of this news release. For a list of the factors that may affect any of the Company’s forward-looking statements, please refer to the Company’s long form prospectus dated December 17, 2024 and other filings made by the Company with the Canadian securities regulatory authorities (which may be viewed under its SEDAR+ profile at www.sedarplus.ca). Light AI disclaims any intention or obligation to update or revise any forward-looking information contained in this new release, whether as a result of new information, future events or otherwise, unless required by applicable law. The forward-looking information included in this news release is expressly qualified in its entirety by this cautionary statement.
For more information, please contact the Company at 604 307 6800 or visit https://light.ai/.
Investor Relations: [email protected]
Media Contact:
Sarah Mawji-Walker
Venture Strategies
[email protected]
ON BEHALF OF THE COMPANY
George Reznik
Chief Financial Officer
